ARTELO BIOSCIENCES, INC. Available-for-sale Securities, Gross Unrealized Loss
ARTELO BIOSCIENCES, INC. (ARTL) reported Available-for-sale Securities, Gross Unrealized Loss of $7.00 thousand for the 3-month period ending 2022-06-30, per its 10-Q filed 2022-08-09.
Discontinued › Expense Statement › Operating Expenses
us-gaap:AvailableForSaleSecuritiesGrossUnrealizedLoss · last filed 2022-08-09
- ARTELO BIOSCIENCES, INC. available-for-sale securities, gross unrealized loss for the quarter ending 2022-06-30 was $7.00K.
- ARTELO BIOSCIENCES, INC. available-for-sale securities, gross unrealized loss for the quarter ending 2022-03-31 was $22.00K.
- ARTELO BIOSCIENCES, INC. available-for-sale securities, gross unrealized loss for the quarter ending 2021-06-30 was $0.00.
- ARTELO BIOSCIENCES, INC. available-for-sale securities, gross unrealized loss for the quarter ending 2021-03-31 was $0.00.
| Period end | Available-for-sale Securities, Gross Unrealized Loss 3 month | Available-for-sale Securities, Gross Unrealized Loss 6 month |
|---|---|---|
| 2022-06-30 | $7.00K 10-Q · filed 2022-08-09 | $29.00K 10-Q · filed 2022-08-09 |
| 2022-03-31 | $22.00K 10-Q · filed 2022-05-12 | |
| 2021-06-30 | $0.00 10-Q · filed 2022-08-09 | $0.00 10-Q · filed 2022-08-09 |
| 2021-03-31 | $0.00 10-Q · filed 2022-05-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| TherapeuticsMD, Inc. (TXMD) | United States | $0.024B | -117.87 |
| NextCure, Inc. (NXTC) | United States | $0.024B | -0.15 |
| Cocrystal Pharma, Inc. (COCP) | United States | $0.022B | |
| AYTU BIOPHARMA, INC (AYTU) | United States | $0.025B | -1.62 |
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |
| Marker Therapeutics, Inc. (MRKR) | United States | $0.020B | -2.86 |
| Cellectar Biosciences, Inc. (CLRB) | United States | $0.020B | -1.03 |
| Shuttle Pharmaceuticals Holdings, Inc. (SHPH) | United States | $0.019B | -0.31 |
| Rocket One Inc. (RKTO) | United States | $0.019B |